Predicting optimal scheduling of drug combinations in lung cancer xenografts using a population PK/PD model
Keywords: bevacizumab, chemotherapy, cytotoxicity, non-small cell lung cancer, Pre-Clinical, SLP2021MIDDSoftware: Monolix®, Simulx™Conference: SLP MIDD+Division: Lixoft
- Bevacizumab-pemetrexed/cisplatin is a first-line therapeutic for advanced nonsquamous non-small cell lung cancer.
- Bevacizumab potentiates pemetrexed/cisplatin (chemotherapy) cytotoxicity by inducing transient tumor vasculature normalization.
- The increase in neoplasm vascular quality because of bevacizumab typically occurs within a period of a few days after administration.
Goal of the study:
- Estimate the optimal gap between administration of bevacizumab and chemotherapy to reach full cytotoxicity activation
By Pauline Traynard
Presented at SLP MIDD+ Virtual Conference March 3-4, 2021